{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:48:34Z","timestamp":1786661314171,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50CA127001"],"award-info":[{"award-number":["P50CA127001"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS069964"],"award-info":[{"award-number":["R01NS069964"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Marnie Rose Foundation"},{"name":"Will Power Foundation"},{"name":"Broach Foundation"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.coviro.2015.03.009","type":"journal-article","created":{"date-parts":[[2015,4,13]],"date-time":"2015-04-13T07:15:14Z","timestamp":1428909314000},"page":"33-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints"],"prefix":"10.1016","volume":"13","author":[{"given":"Hong","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candelaria","family":"Gomez-Manzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisel","family":"Rivera-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick F","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Fueyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2015.03.009_bib0240","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2015.03.009_bib0245","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1586\/14737140.6.5.697","article-title":"Oncolytic adenoviruses as antiglioma agents","volume":"6","author":"Jiang","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.coviro.2015.03.009_bib0250","series-title":"Replicating Viruses for Brain Tumor Treatment","author":"Jiang","year":"2006"},{"key":"10.1016\/j.coviro.2015.03.009_bib0255","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nrc2545","article-title":"Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer","volume":"9","author":"Kirn","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.coviro.2015.03.009_bib0260","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/B978-0-12-398342-8.00004-5","article-title":"Chapter four\u2014design of improved oncolytic adenoviruses","volume":"115","author":"Alemany","year":"2012","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.coviro.2015.03.009_bib0265","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An adenovirus mutant that replicates selectively in p53-deficient human tumor cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.coviro.2015.03.009_bib0270","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nbt0108-37","article-title":"Chinese health biotech and the billion-patient market","volume":"26","author":"Frew","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.coviro.2015.03.009_bib0275","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world's first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.coviro.2015.03.009_bib0280","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.4161\/cbt.216","article-title":"Cancer-specific viruses and the development of ONYX-015","volume":"2","author":"McCormick","year":"2003","journal-title":"Cancer Biol Therapy"},{"key":"10.1016\/j.coviro.2015.03.009_bib0285","first-page":"1666","article-title":"Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus","volume":"23","author":"Xia","year":"2004","journal-title":"Aizheng"},{"key":"10.1016\/j.coviro.2015.03.009_bib0290","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/78638","article-title":"a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer","volume":"6","author":"Khuri","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2015.03.009_bib0295","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.ymthe.2004.07.021","article-title":"A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting","volume":"10","author":"Chiocca","year":"2004","journal-title":"Mol Therapy"},{"key":"10.1016\/j.coviro.2015.03.009_bib0300","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.gt.3301377","article-title":"Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?","volume":"8","author":"Kirn","year":"2001","journal-title":"Gene Ther"},{"key":"10.1016\/j.coviro.2015.03.009_bib0305","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1128\/MCB.5.10.2552","article-title":"Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport","volume":"5","author":"Babiss","year":"1985","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.coviro.2015.03.009_bib0310","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1002\/j.1460-2075.1989.tb08360.x","article-title":"The adenovirus E1B 55 kd protein influences mRNA transport via an intranuclear effect on RNA metabolism","volume":"8","author":"Leppard","year":"1989","journal-title":"EMBO J"},{"key":"10.1016\/j.coviro.2015.03.009_bib0315","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1128\/MCB.6.2.470","article-title":"The adenovirus E1B-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs","volume":"6","author":"Pilder","year":"1986","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.coviro.2015.03.009_bib0320","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nm0697-639","article-title":"ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. [see comment]","volume":"3","author":"Heise","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2015.03.009_bib0325","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ccr.2004.11.012","article-title":"Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity","volume":"6","author":"O'Shea","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coviro.2015.03.009_bib0330","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/334124a0","article-title":"Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product","volume":"334","author":"Whyte","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2015.03.009_bib0335","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1128\/JVI.62.1.257-265.1988","article-title":"Two regions of the adenovirus early region 1A proteins are required for transformation","volume":"62","author":"Whyte","year":"1988","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.03.009_bib0340","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0092-8674(89)90984-7","article-title":"Cellular targets for transformation by the adenovirus E1A proteins","volume":"56","author":"Whyte","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2015.03.009_bib0345","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.coviro.2015.03.009_bib0350","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/80474","article-title":"An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy","volume":"6","author":"Heise","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2015.03.009_bib0355","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1126\/science.274.5293.1672","article-title":"Cancer cell cycles","volume":"274","author":"Sherr","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.coviro.2015.03.009_bib0360","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.coviro.2015.03.009_bib0365","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1073\/pnas.94.7.3352","article-title":"HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses","volume":"94","author":"Tomko","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2015.03.009_bib0370","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","article-title":"Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment","volume":"73","author":"Wickham","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2015.03.009_bib0375","series-title":"Adenoviruses: Basic Biology to Gene Therapy","author":"Seth","year":"1999"},{"key":"10.1016\/j.coviro.2015.03.009_bib0380","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1054-3589(08)60140-4","article-title":"Human adenovirus vectors for gene transfer into mammalian cells","volume":"40","author":"Hitt","year":"1997","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.coviro.2015.03.009_bib0385","first-page":"5738","article-title":"Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer","volume":"58","author":"Miller","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.coviro.2015.03.009_bib0390","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","article-title":"Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway","volume":"95","author":"Fueyo","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.coviro.2015.03.009_bib0395","first-page":"380","article-title":"Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery","volume":"49","author":"Bello","year":"2001","journal-title":"Neurosurgery"},{"key":"10.1016\/j.coviro.2015.03.009_bib0400","first-page":"120","article-title":"A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency","volume":"7","author":"Suzuki","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coviro.2015.03.009_bib0405","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.coviro.2015.03.009_bib0410","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: genesis to genetic engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2015.03.009_bib0415","first-page":"38","article-title":"The host response to cancer virotherapy","volume":"10","author":"Chiocca","year":"2008","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.coviro.2015.03.009_bib0420","doi-asserted-by":"crossref","first-page":"e97407","DOI":"10.1371\/journal.pone.0097407","article-title":"Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model","volume":"9","author":"Jiang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2015.03.009_bib0425","doi-asserted-by":"crossref","first-page":"e947872","DOI":"10.4161\/21624011.2014.947872","article-title":"Healing after death: anti-tumor immunity induced by oncolytic adenoviral therapy","volume":"3","author":"Jiang","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.coviro.2015.03.009_sbref0430","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.coviro.2015.03.009_bib0435","doi-asserted-by":"crossref","first-page":"e24720","DOI":"10.4161\/onci.24720","article-title":"Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy","volume":"2","author":"Loi","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.coviro.2015.03.009_sbref0440","doi-asserted-by":"crossref","first-page":"226ra232","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2015.03.009_sbref0445","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.coviro.2015.03.009_bib0450","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/gt.2011.176","article-title":"Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4","volume":"19","author":"Dias","year":"2012","journal-title":"Gene Ther"},{"key":"10.1016\/j.coviro.2015.03.009_bib0455","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/mt.2009.205","article-title":"Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL","volume":"18","author":"Huang","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2015.03.009_bib0460","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1128\/JVI.02032-10","article-title":"Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity","volume":"86","author":"Jiang","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2015.03.009_sbref0465","doi-asserted-by":"crossref","DOI":"10.1038\/onc.2014.452","article-title":"C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy","author":"Klein","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.coviro.2015.03.009_sbref0470","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/B978-0-12-398342-8.00003-3","article-title":"Chapter three\u2014Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds","volume":"115","author":"Wold","year":"2012","journal-title":"Adv Cancer Res"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625715000401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625715000401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T16:29:40Z","timestamp":1598891380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625715000401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":47,"alternative-id":["S1879625715000401"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2015.03.009","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2015.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}